Inventor
XIAOLING SONG
Inventor
CN
Overview
Patents· 5 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%
C07DHeterocyclic compounds24%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium12%
C07KPeptides6%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms6%
G01NInvestigating or analysing materials by determining their chemical or physical properties6%
PatentTitleYear
12,564,638EGFR protein degradant and anti-tumor application thereof202612,390,532ALK protein regulator and anti-tumor application thereof202512,226,424Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates202511,771,709ALK protein degradation agent and anti-tumor application thereof202311,186,879Methods and nucleic acids for analyses of cellular proliferative disorders2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021Patents assigned to EPIGENOMICS AG (1)· patent assignee history
2021Based in US· patent location history
2023–2026Patents assigned to UNIV SHANGHAI TECHNOLOGY (4)· patent assignee history
2023–2026Based in CN· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| UNIV SHANGHAI TECHNOLOGY | 4 | 2023–2026 |
| EPIGENOMICS AG | 1 | 2021 |
Locations
| Location | Patents | Span |
|---|---|---|
| CN | 4 | 2023–2026 |
| US | 1 | 2021 |